Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients.

European Journal of Gastroenterology & Hepatology
Hany M ElsadekAlaa A Farag

Abstract

Though direct-acting antiviral agents (DAAs) therapy is associated with a high cure rate of hepatitis C virus infection, a potential risk of serious adverse events (SAEs) exists. The aim of this study was to determine the incidence and predictors of morbidity and mortality related to DAAs therapy. This prospective study was conducted on a real word cohort of 1562 treatment naïve chronic hepatitis C (CHC) Egyptian patients, who received 12-weeks therapy with sofosbuvir (SOF) plus daclatasvir (DCV) ± ribavirin (RBV). The incidence and predictors of SAEs and mortality during treatment course and over the following 12 weeks were recorded. The mean age of study participants was 51.38 ± 9.70 years (55.22%, males). Liver cirrhosis was defined in 72.4% of participants. SAEs were recorded in 120 participants (7.68%), including hepatic decompensation, gastrointestinal bleeding, anemia and hepatocellular carcinoma. Nine patients (0.58%) died and 69 patients (4.42%) discontinued therapy due to SAEs. Severity of cirrhosis was the significant predictor of morbidities and mortality. Hepatic decompensation was predicted by baseline serum albumin [cutoff value: 3.00 g/dL, area under the receiver operating characteristic curve (AUROC): 0.953] an...Continue Reading

References

Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Jun 28, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·F Abdel-AzizI Sallam
Feb 12, 2009·Liver International : Official Journal of the International Association for the Study of the Liver·Daniel Lavanchy
Apr 10, 2013·Journal of Hepatology·Jean-Michel Pawlotsky
Apr 26, 2015·Journal of Hepatology·UNKNOWN European Association for Study of Liver
Jan 21, 2016·Alimentary Pharmacology & Therapeutics·D Banerjee, K R Reddy
Jan 30, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Vincent LeroyAlexander J Thompson
May 1, 2016·Hepatology International·Masao OmataShiv Kumar Sarin
Jun 9, 2016·Liver International : Official Journal of the International Association for the Study of the Liver·Amr KandeelMaha Talaat
Sep 30, 2016·World Journal of Gastroenterology : WJG·Arnolfo PetruzzielloCarmela Cacciapuoti
Feb 9, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Carlos Fernández CarrilloJosé Luis Calleja
Feb 13, 2017·Journal of Hepatology·Jose Luis CallejaUNKNOWN Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group
Oct 23, 2018·World Journal of Gastroenterology : WJG·Dalia OmranMohamed El Kassas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.